

## Aromatic interactions effect on binding and function of agonist at Serotonin 5-HT<sub>2C</sub> receptor. Homology Modeling, Docking, Molecular Dynamics, and Experimental study.

**Tania Cordova-Sintjago<sup>1</sup>, Nancy Villa<sup>1</sup>, Lijuan Fang<sup>1</sup>, Adam Vincek<sup>1</sup>, Raymond G. Booth<sup>1,2</sup>**

<sup>1</sup>Department of Medicinal Chemistry, College of Pharmacy University of Florida, Gainesville, FL 32610

<sup>2</sup>Center for Drug Discovery, Dept. Pharmaceutical Sciences, Northeastern University, Boston, MA 02115

Activation of the human serotonin (5-hydroxytryptamine, 5-HT) 5-HT<sub>2C</sub> G protein-coupled receptor (GPCR) is therapeutic for neuropsychiatric disorders and obesity, however, activation of 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> GPCRs is associated with adverse psychiatric and cardiac effects, respectively. Ligands specific for activation of 5-HT<sub>2C</sub> receptors have been difficult to achieve because the 5-HT<sub>2</sub> GPCR family shares ~75% transmembrane (TM) sequence identity. For the human 5-HT<sub>2A</sub> receptor, molecular modeling and mutagenesis results indicate conserved TM helix 6 aromatic residues W6.48, F6.51, and F6.52 are important for ligand binding and agonist vs. inverse agonist/antagonist functional activity (Kroeze et al., 2002), however, corresponding results for the 5-HT<sub>2C</sub> receptor have not been reported. Accordingly, novel GPCR homology molecular modeling studies, molecular dynamics (MD) simulations, and mutagenesis experiments were undertaken here to characterize molecular determinants for 5-HT<sub>2C</sub> specific activation by novel (vs. known) ligands. Affinity and function (phospholipase C [PLC] signaling) of 5-HT in comparison to the novel 5-HT<sub>2C</sub> agonist/5-HT<sub>2A/2B</sub> inverse agonist (–)-*trans*-(2*S*,4*R*)-4-phenyl-2-*N,N*-dimethylamino-1,2,3,4-tetrahydronaphthalene (PAT) (Booth et al., 2009), and several PAT analogs (Vincek & Booth, 2009), were assessed at the wild type (WT) and W6.48A, F6.51A, and F6.52A point-mutated recombinant human 5-HT<sub>2C</sub> receptors in HEK cells. Homology model development for WT and point-mutated 5-HT<sub>2C</sub> receptors, ligand docking, and MD simulations in a lipid POPC membrane (Cordova-Sintjago et al., 2012) were undertaken to delineate ligand–receptor molecular interactions at the 5-HT (orthosteric) binding pocket. At the WT 5-HT<sub>2C</sub> receptor model, docking results indicate interactions in the binding pocket are different for PAT analogs compared to 5-HT. There were possible  $\pi$ - $\pi$  stacking interactions between the PATs C(4) phenyl moiety and the 5-HT<sub>2C</sub> W6.48 indole moiety. The PATs aromatic tetrahydronaphthalene moiety docked close and nearly parallel to the 5-HT<sub>2C</sub> F6.51 aromatic ring, suggesting  $\pi$ - $\pi$  stacking interactions. No direct interactions were observed between the PAT analogs and the 5-HT<sub>2C</sub> F6.52 residue. At the W6.48A and F6.51A 5-HT<sub>2C</sub> receptor models, PATs had no relevant interactions (ditto for the F6.52A model). For 5-HT, two distinct poses docked at the WT 5-HT<sub>2C</sub> model and neither pose indicated  $\pi$ - $\pi$  stacking interactions between 5-HT and W6.48, however, in both poses, the 5-HT indole moiety interacted with F6.51 and F6.52. Experimental studies using the point-mutated 5-HT<sub>2C</sub> receptors indicated W6.48 is essential for binding to PAT analogs with a C(4) phenyl moiety but not with a C(4) cyclohexyl moiety. Lesser affinity differences were noted at the F6.51A 5-HT<sub>2C</sub> receptor and no differences for the F6.52A 5-HT<sub>2C</sub> receptor, in comparison to WT receptors. The W6.48 residue and to a lesser extent the F6.51 and F6.52 residues were required for PAT-mediated activation of 5-HT<sub>2C</sub> PLC signaling. Interestingly, at the F6.51A, F6.52A, and W6.48A 5-HT<sub>2C</sub> receptors, the C(4) cyclohexyl analog was an agonist whereas it was an inverse agonist at the WT 5-HT<sub>2C</sub> receptor. Ligand docking and MD simulations showed that the C(4) cyclohexyl moiety undergoes conformational changes that apparently differentially stabilize agonist vs. inverse agonist 5-HT<sub>2C</sub> conformations, involving the F6.51, F6.52, and W6.48 residues. Results suggest ligand binding and functional interaction with W6.48, F6.51, and F6.52 residues may be different for 5-HT<sub>2C</sub> receptors in comparison to 5HT<sub>2A</sub> receptors, which informs 5HT<sub>2C</sub>-specific ligand design for drug development purposes. Moreover, computational results help predict and explain experimental outcomes for drug discovery purposes. Support: NIH RO1 DA023928, DA030989, MH081193. Keywords: GPCR, homology modeling, docking, molecular dynamics, serotonin. Booth et al., Eur. J. Pharmacol. 615:1, 2009; Booth & Vincek, Tetrahedron Lett. 50:5107, 2009; Cordova-Sinjago et al., Int. J Quant. Chem. 112:140, 2012; Kroeze et al., Curr Top Med Chem. 2:507, 2002.